Biostage, Inc. (NASDAQ:BSTG)‘s stock had its “hold” rating reaffirmed by equities research analysts at Maxim Group in a research report issued to clients and investors on Monday.

Shares of Biostage (NASDAQ BSTG) traded up 17.3696% during midday trading on Monday, reaching $0.5399. The company’s stock had a trading volume of 5,655,523 shares. The company has a 50 day moving average of $0.43 and a 200-day moving average of $0.41. The stock’s market capitalization is $20.04 million. Biostage has a 52 week low of $0.22 and a 52 week high of $1.42.

Biostage (NASDAQ:BSTG) last announced its earnings results on Thursday, May 11th. The biotechnology company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.09. Equities research analysts predict that Biostage will post ($0.81) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Biostage, Inc. (NASDAQ:BSTG) Given Hold Rating at Maxim Group” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/08/07/biostage-inc-nasdaqbstg-given-hold-rating-at-maxim-group.html.

About Biostage

Biostage, Inc, formerly Harvard Apparatus Regenerative Technology, Inc, is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient’s own cells.

Receive News & Ratings for Biostage Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostage Inc. and related companies with MarketBeat.com's FREE daily email newsletter.